Johnson & Johnson Announces Results From A Subgroup Analysis Of The Phase 3 CARTITUDE-4 Study Showing CARVYKTI Improved Progression-Free Survival And Deepened Responses Versus Two Standard Therapies For Patients With Functional High-Risk Multiple Myelo…
73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1CHICAGO, June 3, 2024
